News

404

David W. Anderson, Ph.D.

David W. Anderson, Ph.D.

NON-CLINICAL AND TRANSLATIONAL DEVELOPMENT

David Anderson, Ph.D. (Immunology and Medical Microbiology) has deep expertise in target-based drug discovery/ development and personalized molecular diagnostics in inflammation and oncology. He built and managed innovative drug discovery and development companies acquired by Celgene Corporation Cypress Bioscience and Roche.

Anderson is currently the Chief Scientific Officer of Capella Therapeutics and has held senior positions at Ignyta (CSO/ VP Cancer Biology), Eclipse Therapeutics (VP R&D acquired by Bionomics), Proprius Pharmaceuticals, (CSO) Celgene Corporation (CSO/Senior VP), Johnson & Johnson (Senior Director Immunotherapy/ Inflammation Drug Discovery), and Monsanto/ Searle (Senior Group Leader). He was leader or member of teams responsible for development of six FDA approved drugs (Procrit®, Leustatin®, Revlimid® and Rozlytrek® for hematology/oncology indications, Zubrin® for veterinary arthritis, and Surfaxin® for respiratory distress syndrome), two NDAs, and ten INDs, two Personalized Diagnostic products (AVISE-PG® & AVISE-MCV®) for rheumatoid arthritis. He has served as a consultant for numerous other companies (Johnson & Johnson, Celgene, Santarus/Salix, Adventrx, aTyr Pharma), VC and investment firms (Kleiner Perkins Caufield & Byers, Venrock Ventures, CID Equity Partners & Clarian Health, City Hill Ventures) and as an SAB member (Visionary Pharmaceuticals, Ivogen, and CryoCrate).

He has held academic positions at the University of Colorado Health Sciences Center and The Scripps Research Institution. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/immunomodulatory and cancer drugs, and has refereed articles for peer-reviewed journals such as Science, Journal of Rheumatology, and Journal of Pharmacology and Experimental Therapeutics. Anderson also has an outstanding record of scientific publications and presentations (35 peer reviewed publications and over 50 presentations/abstracts) and has received several research awards and 10 patents for his innovative research.

NON-CLINICAL AND TRANSLATIONAL DEVELOPMENT

David Anderson, Ph.D. (Immunology and Medical Microbiology) has deep expertise in target-based drug discovery/ development and personalized molecular diagnostics in inflammation and oncology. He built and managed innovative drug discovery and development companies acquired by Celgene Corporation Cypress Bioscience and Roche.

Anderson is currently the Chief Scientific Officer of Capella Therapeutics and has held senior positions at Ignyta (CSO/ VP Cancer Biology), Eclipse Therapeutics (VP R&D acquired by Bionomics), Proprius Pharmaceuticals, (CSO) Celgene Corporation (CSO/Senior VP), Johnson & Johnson (Senior Director Immunotherapy/ Inflammation Drug Discovery), and Monsanto/ Searle (Senior Group Leader). He was leader or member of teams responsible for development of six FDA approved drugs (Procrit®, Leustatin®, Revlimid® and Rozlytrek® for hematology/oncology indications, Zubrin® for veterinary arthritis, and Surfaxin® for respiratory distress syndrome), two NDAs, and ten INDs, two Personalized Diagnostic products (AVISE-PG® & AVISE-MCV®) for rheumatoid arthritis. He has served as a consultant for numerous other companies (Johnson & Johnson, Celgene, Santarus/Salix, Adventrx, aTyr Pharma), VC and investment firms (Kleiner Perkins Caufield & Byers, Venrock Ventures, CID Equity Partners & Clarian Health, City Hill Ventures) and as an SAB member (Visionary Pharmaceuticals, Ivogen, and CryoCrate).

He has held academic positions at the University of Colorado Health Sciences Center and The Scripps Research Institution. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/immunomodulatory and cancer drugs, and has refereed articles for peer-reviewed journals such as Science, Journal of Rheumatology, and Journal of Pharmacology and Experimental Therapeutics. Anderson also has an outstanding record of scientific publications and presentations (35 peer reviewed publications and over 50 presentations/abstracts) and has received several research awards and 10 patents for his innovative research.

Scroll to top